-+ 0.00%
-+ 0.00%
-+ 0.00%

ANIXA BIOSCIENCES INC: PHASE 1 STUDY MET PRIMARY ENDPOINTS, SHOWED SAFETY AND TOLERABILITY AT MAXIMUM TOLERATED DOSE

Reuters·04/01/2026 12:50:09

Please log in to view news